Chapters

Transcript

Video

As a medical cardiologist treating patients for secondary prevention of ASCVD, can you share with us the outcomes and disease course of patients you have managed with PCSK9 inhibitors? Has the cost reductions affected your appetite for these agents?

As a medical cardiologist treating patients for secondary prevention of ASCVD, can you share with us the outcomes and disease course of patients you have managed with PCSK9 inhibitors? Has the cost reductions affected your appetite for these agents?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

R. Scott Wright, MD

R. Scott Wright, MD

Professor of Medicine
Department of Cardiovascular Medicine
Cardiovascular Division
Mayo Clinic